A prospective clinical trial of open-label etanercept for the treatment of hidradenitis suppurativa

Journal of the American Academy of Dermatology

Volumn 60, Issue 4, 2009, Pages 565-573

  Lee, Robert A ^a   Dommasch, Erica ^a   Treat, James ^a   Sciacca Kirby, Joslyn ^b   Chachkin, Samuel ^a   Williams, Jennifer ^a   Shin, Daniel B ^a   Leyden, James J ^a   Vittorio, Carmela ^a   Gelfand, Joel M ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

Author keywords

clinical trial; efficacy; etanercept; hidradenitis suppurativa; quality of life; safety; tumor necrosis factor inhibitor

Indexed keywords

ANTIBIOTIC AGENT; ETANERCEPT;

ADULT; ARTICLE; CELLULITIS; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROL GROUP; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DERMATOLOGY; DERMATOLOGY LIFE QUALITY INDEX; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FLU LIKE SYNDROME; HUMAN; HYPERTENSION; INJECTION SITE CONTUSION; INJECTION SITE ERYTHEMA; INJECTION SITE IRRITATION; MALE; MUSCLE CRAMP; NAUSEA; OUTCOME ASSESSMENT; PAIN; PARESTHESIA; PATIENT SATISFACTION; PHASE 2 CLINICAL TRIAL; PHYSICIAN GLOBAL ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUALITY OF LIFE; SCORING SYSTEM; SIDE EFFECT; SINGLE DRUG DOSE; SKIN INFECTION; SUPPURATIVE HIDRADENITIS; THORAX PAIN; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION;

ADULT; FEMALE; HIDRADENITIS SUPPURATIVA; HUMANS; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RECEPTORS, TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR-ALPHA;

EID: 61849120256     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaad.2008.11.898     Document Type: Article

References (31)

1. Lee R.A., Yoon A., and Kist J. Hidradenitis suppurativa: an update. Adv Dermatol 23 (2007) 289-306
2. Jemec G.B. Medical treatment of hidradenitis suppurativa. Expert Opin Pharmacother 5 (2004) 1767-1770
3. Jemec G.B., Heidenheim M., and Nielsen N.H. Hidradenitis suppurativa-characteristics and consequences. Clin Exp Dermatol 21 (1996) 419-423
4. Revuz J.E., Canoui-Poitrine P., Wolkenstein P., Viallette C., Gabison G., Pouget F., et al. Prevalence and factors associated with hidradenitis suppurativa: results from two case-control studies. J Am Acad Dermatol 59 (2008) 596-601
5. Jemec G.B., Heidenheim M., and Nielsen N.H. The prevalence of hidradenitis suppurativa and its potential precursor lesions. J Am Acad Dermatol 35 (1996) 191-194
6. Wolkenstein P., Loundou A., Barrau K., Auquier P., and Revuz J. Quality of life impairment in hidradenitis suppurativa: a study of 61 cases. J Am Acad Dermatol 56 (2007) 621-623
7. Rosi Y.L., Lowe L., and Kang S. Treatment of hidradenitis suppurativa with infliximab in a patient with Crohn's disease. J Dermatolog Treat 16 (2005) 58-61
8. Trent J.T., and Kerdel F.A. Tumor necrosis factor alpha inhibitors for the treatment of dermatologic diseases. Dermatol Nurs 17 (2005) 97-107
9. LaDuca J. Targeting tumor necrosis factor alpha. New drugs used to modulate inflammatory diseases. Dermatol Clin 19 (2001) 617-635
10. Adams D.R., Gordon K.B., Devenyi A.G., and Ioffreda M.D. Severe hidradenitis suppurativa treated with infliximab infusion. Arch Dermatol 139 (2003) 1540-1542
11. Sullivan T.P., Welsh E., Kerdel F.A., Burdick A.E., and Kirsner R.S. Infliximab for hidradenitis suppurativa. Br J Dermatol 149 (2003) 1046-1049
12. Elkjaer M., Dinesen L., Benazzato L., Rodriguez J., Løgager V., and Munkholm P. Efficacy of infliximab treatment in patients with severe fistulizing hidradenitis. Journal of Crohn's and Colitis 2 (2008) 241-245
13. Antonucci A., Negosanti M., Negosanti L., Iozzo I., and Varotti C. Acne inversa treated with infliximab: different outcomes in 2 patients. Acta Derm Venereol 88 (2008) 274-275
14. Usmani N., Clayton T.H., Everett S., and Goodfield M.D. Variable response of hidradenitis suppurativa to infliximab in four patients. Clin Exp Dermatol 32 (2007) 204-205
15. Yamauchi P. Adalimumab in the management of hidradenitis suppurativa. J Am Acad Dermatol 56 (2007) AB41
16. Moschella S. Is there a role for infliximab in the current therapy of hidradenitis suppurativa? A report of three treated cases. Int J Dermatol 46 (2007) 1287-1291
17. Fardet L., Dupuy A., Kerob D., Levy A., Allez M., Begon E., et al. Infliximab for severe hidradenitis suppurativa: transient clinical efficacy in 7 consecutive patients. J Am Acad Dermatol 56 (2007) 624-628
18. Fernández-Vozmediano J.M., and Armario-Hita J.C. Infliximab for the treatment of hidradenitis suppurativa. Dermatology 215 (2007) 41-1
19. Henderson Jr. R.L. Treatment of atypical hidradenitis suppurativa with the tumor necrosis factor receptor-Fc fusion protein etanercept (case reports). J Drugs Dermatol 5 (2006) 1010-1011
20. Zangrilli A., Esposito M., Mio G., Mazzotta A., and Chimenti S. Long-term efficacy of etanercept in hidradenitis suppurativa. J Eur Acad Dermatol Venereol 22 (2008) 1260-1262
21. Moul D.K., and Korman N.J. Severe hidradenitis suppurativa treated with adalimumab. Arch Dermatol 142 (2006) 1110-1112
22. Scheinfeld N. Treatment of coincident seronegative arthritis and hidradenitis suppurativa with adalimumab. J Am Acad Dermatol 55 (2006) 163-164
23. Hurley H. Axillary hyperhidrosis, apocrine bromhidrosis, hidradenitis suppurativa and familial benign pemphigus: surgical approach. In: Roenigk RK, Roenigk HH, eds. Dermatologic surgery: principles and practice. New York: Marcel Dekker Inc; 1996. pp. 623-645.
24. Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials 10 (1989) 1-10
25. Sachs D.D., and Gordon A.T. Hidradenitis suppurativa of glands of Moll. Arch Ophthalmol 77 (1967) 635-636
26. Hongbo Y., Thomas C.L., Harrison M.A., Salek M.S., and Finlay A.Y. Translating the science of quality of life into practice: what do dermatology life quality index scores mean?. J Investig Dermatol 125 (2005) 659-664
27. Giamarellos-Bourboulis E.J., Pelekanou E., Antonopoulou A., Petropoulou H., Baziaka F., Karagianni V., et al. An open-label phase II study of the safety and efficacy of etanercept for the therapy of hidradenitis suppurativa. Br J Dermatol 158 (2008) 567-572
28. Cusack C., and Buckley C. Etanercept: effective in the management of hidradenitis suppurativa. Br J Dermatol 154 (2006) 726-729
29. Mekkes J.R., and Bos J.D. Long-term efficacy of a single course of infliximab in hidradenitis suppurativa. Br J Dermatol 158 (2008) 370-374
30. Clark L., and Lebwohl M. The effect of weight on the efficacy of biologic therapy in patients with psoriasis. J Am Acad Dermatol 58 (2008) 443-446
31. Thomson Reuters 2008: Nicomide drug monograph. The Physicians' Desk Reference Web site. Available at http://www.pdr.net/druginformation/FDAMonographsInfo.aspx?MonographID=1762. Accessed December 30, 2008